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FGF21 is a protein withmultiple metabolic actions, currently a bright star beckoning on themetabolic disease
therapeutic horizon. Gaich et al. (2013) present the first clinical efficacy trial for an FGF21 mimetic, finding
robust lipid-lowering effects, some reduction in body weight, but surprisingly modest effects on glucose
homeostasis.Fibroblast growth factor 21 (FGF21) is a
181-amino-acid-secreted protein that is
produced in the liver, white and brown
adipose tissue, and endocrine and
exocrine pancreas. Since the unexpected
discovery of a metabolic role for FGF21 in
2005 (Kharitonenkov et al., 2005), FGF21
administration to rodents and nonhuman
primates has been shown to reduce liver
and circulating triglyceride levels and to
increase insulin sensitivity, reducing
hepatic glucose production and plasma
glucose and increasing adipose glucose
uptake. FGF21 also causes both brown
fat activation and reduction in adipose
tissue and body weight and improves islet
b cell mass and function. In mice, overex-
pression of FGF21 produces additional
phenotypes consistent with energy-
conserving effects, including a smaller
body size attributed to growth hormone
resistance, easier entry into torpor, and
decreased bone mass. Although it is diffi-
cult to weave a single unifying theme,
FGF21 appears to be crucial for the regu-
lation of fuel use and in adaptation to star-
vation (reviewed in Potthoff et al., 2012).
These effects point to FGF21 mimetics
as potential therapeutic agents for the
treatment of diabetes, obesity, and
dyslipidemia. Now, Gaich et al. (2013)
report the first clinical efficacy trial of
LY2405319, a modified FGF21. They find
that LY2405319 improves the lipid profile
of obese, diabetic patients, but does not
significantly affect weight or glucose
homeostasis.
The molecular mechanisms by which
FGF21 produces its physiologic effects
are still being elucidated. FGF21 tran-
scription is induced by peroxisome prolif-
erator-activated receptor-g (PPARg) and
PPARa activators, including drugs that
are used to treat diabetes (thiazolidine-diones) and hyperlipidemia (fibrates),
respectively. FGF21 signals by binding
to and activating the c splicing isoforms
of FGFR1, FGFR2, and FGFR3, with
FGFR1c likely being the principal re-
ceptor. Signaling requires the b-klotho
coreceptor, with tissue-specific respon-
siveness chiefly determined by the tissue
distribution of b-klotho. Adipose tissue is
required for the antidiabetic actions of
FGF21 (Wu et al., 2011). FGF21 increases
adiponectin production by adipose tis-
sue, suggesting that adiponectin trans-
mits the effects of FGF21 to muscle and
liver (Holland et al., 2013; Lin et al.,
2013). However, recent observations
make clear that the relevant mechanisms
are evenmore complex: in adipose tissue,
FGF21 is not simply a downstream target
of PPARg, but also contributes to PPARg
activity, indicating a bidirectional interac-
tion (Dutchak et al., 2012), and FGF21 is
not required for thiazolidinedione action
(Adams et al., 2013).
The excitement about FGF21 as a
potential therapeutic agent is reflected in
the creative efforts that have been ex-
pended to produce FGF21 mimetics,
including LY2405319. Many factors need
to be considered in these efforts,
including potency, selectivity, pharmaco-
kinetics (half-life, brain penetration), intel-
lectual property, and manufacturing
(feasibility, cost, stability). LY2405319,
for example, contains a synthetic disulfide
bond that increases the molecule’s phys-
ical stability, as well as mutations that
facilitate its production in yeast. Despite
these modifications, LY2405319 has a
specificity and potency comparable to
FGF21 (Kharitonenkov et al., 2013).
Another important consideration is the
protein’s half-life; a longer half-life
allows less-frequent dosing, obviatingCell Metabolism 18, Sthe need for daily injections. Whereas
LY2405319’s half-life appears to be
similar to that of native FGF21, other mi-
metics have prolonged half-lives, due to
innovations such as coupling to poly-
ethylene glycol, fusion with an immuno-
globulin constant domain, and coupling
of two FGF21 molecules to a single anti-
body (Table 1). LY2405319 was the first
FGF21 mimetic to reach a phase 1 clinical
trial.
As Gaich et al. (2013) report,
LY2405319 at 0, 3, 10, or 20 mg was
injected into obese subjects with type 2
diabetes once daily for 28 days, with
approximately 10 patients completing
treatment per dose. The drug improved
the patients’ lipid profiles, lowering low-
density lipoprotein (LDL) levels 20%–
30%, total cholesterol 15%–19%, and
triglycerides 26%–46%, and raising
high-density lipoprotein (HDL) levels
15%–20%. Subjects receiving the drug
also lost 1.3–1.5 kg more than the
placebo-treated patients, although this
amount did not reach statistical signifi-
cance. There was also a hint of improved
glucose homeostasis (lower glucose and
insulin levels), but the changes were
surprisingly small and not statistically
significant.
One challenge with modified proteins is
that they may be perceived as foreign
by the immune system. The immune
response can range from injection site
irritation, to development of antidrug anti-
bodies without effect, to antibodies that
alter pharmacokinetics, neutralize drug,
or neutralize endogenous FGF21, to
hypersensitivity reactions. In Gaich et al.
(2013), some patients developed injection
site reactions, about half developed
antibodies, and there was one serious
hypersensitivity reaction. However, theeptember 3, 2013 ª2013 Elsevier Inc. 307
Table 1. FGF21 Mimetic Molecules
Name and Reference Company FGF21 Modification Modification Result Half-Life* Binding Specificity*
LY2405319
Kharitonenkov et al., 2013
Lilly L118C, A134C
S167A
DHPIP
new disulfide to increase stability
prevent glycosylation in yeast
monodisperse product
unchanged FGFR1c/b-klotho
FGFR2c/b-klotho
FGFR3c/b-klotho
PEG FGF21
Mu et al., 2012
Ambrx/Merck R131pAcF
couple to PEG
single reactive site for coupling
increase t1/2
increased FGFR1c/b-klotho
FGFR2c/b-klotho
FGFR3c/b-klotho
Fc-FGF21(RG)
Ve´niant et al., 2012
Amgen L98R
P171G
fusion to Fc
reduce aggregation
reduce in vivo degradation
increase t1/2
increased FGFR1c/b-klotho
FGFR2c/b-klotho
FGFR3c/b-klotho
CVX-343
Huang et al., 2013
Pfizer A129C
couple to Ab
single reactive site for coupling
increase t1/2
increased FGFR1c/b-klotho
FGFR2c/b-klotho
FGFR3c/b-klotho
FGFR1b/1c agonist antibody
Wu et al., 2011
Genentech not based on FGF21 increase t1/2 increased FGFR1b, FGFR1c
mimAb1 agonist antibody
Foltz et al., 2012
Amgen not based on FGF21 increase t1/2 increased FGFR1c/b-klotho
FGFR1c/b-klotho bispecific
Smith et al., 2013
Amgen not based on FGF21 increase t1/2 increased FGFR1c/b-klotho
The table lists published FGF21mimetics, along with their incorporated modifications, half-life, and binding specificity. Standard one-letter amino acid
abbreviations are used; D, deletion; pAcF, p-acetylphenylalanine; PEG, polyethylene glycol; t1/2, half-life; Fc, antibody constant domain; Ab, antibody.
*Some half-lives and binding specificities are inferred.
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izing and did not alter the pharmacoki-
netics of the drug, suggesting that the
clinical efficacy of LY2405319 in this trial
was likely not compromised by the im-
mune response.
How do these results affect the pros-
pects for clinical use of FGF21 mimetics?
The results of the LY2405319 trial consti-
tute clinical proof-of-concept that FGF21
mimetics improve lipid profiles. Future
studies for lipid efficacy could focus on
larger trials, optimizing treatment regi-
mens and drug combinations, and
identification of the optimum patient
population. For weight loss, the 28 days
in the current trial is shorter than the usual
12-week duration for proof-of-concept
weight loss trials, precluding adequate
assessment of weight loss efficacy. One
issue not addressed by the LY2405319
trial is bone health. FGF21 was recently
found to decrease bone mass, with inhibi-
tion of osteoblastogenesis (Wei et al.,
2012). As Gaich et al. (2013) did not
monitor bone biomarkers, this aspect
will need to be examined in future clinical
studies.
Understanding the lack of efficacy in
reducing fasting glucose levels will also
require further analysis. Is FGF21 intrinsi-
cally a poor choice for treating diabetes,
do LY2405319 and FGF21 act differently,308 Cell Metabolism 18, September 3, 2013 ªor was the trial design responsible?
The adiponectin levels in this trial may
not have plateaued, suggesting that
increased exposure to drug could further
increase adiponectin levels to produce a
greater effect on diabetes. Would a
longer-acting mimetic perform better?
Three FGF21 mimetics not based on
FGF21 itself (Table 1) may make it
possible to target a different spectrum of
physiologic effects. One mimetic is a
monoclonal antibody that activates
FGFR1c, but not FGFR2c or FGFR3c,
and does not require b-klotho. Another
activating monoclonal antibody is
specific for FGFR1c/b-klotho, and yet
another mimetic fuses two synthetic
proteins that bind FGFR1c and b-klotho.
The variety of engineered FGF21 mime-
tics should facilitate elucidation of the
roles of FGFR1c versus FGFR2c/FGFR3c
signaling and whether the lipid, glucose,
growth, and bone phenotypes can be
differentially impacted. Although not the
hoped-for result, the glucose and insulin
data are a minor setback. Many of the
questions can be addressed with further
clinical trials and other mimetics.
Dyslipidemia, diabetes, and obesity
are associated major health problems in
need of improved therapeutic agents,
and it is exciting to see the first clinical
efficacy data for a new therapeutic2013 Elsevier Inc.approach. We look forward to further
studies with FGF21 mimetics to address
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Melanocortin receptors are critical modulators of energy balance and glucose homeostasis. Companion
studies published in Science (Asai et al., 2013; Sebag et al., 2013) establish a role for melanocortin receptor
accessory protein 2 (Mrap2) in regulating melanocortin receptor activity and in the development of obesity in
zebrafish, rodents, and humans.The rates of obesity and diabetes are ris-
ing around the world. Although environ-
mental conditions have been implicated
in these diseases, accumulating evidence
suggests genetics also contributes to
early-onset and severe obesity. Themela-
nocortin system provides one example
(Balthasar et al., 2005; Cone, 2006;
Greenfield et al., 2009; Sohn et al.,
2013). It is comprised of ligands and a
family of receptors (MC1–5 receptors)
that directly link to a myriad of bio-
physiological systems regulating food
intake, energy expenditure, body length,
and glucose metabolism (Cone, 2006).
Notably, disruptions of MC4 receptors in
rodents result in severe obesity and dia-
betes (Cone, 2006). Moreover, mutations
of MC4 receptors in humans lead to
analogous deficits of metabolism and
are the most common monogenic form
of human obesity (Cone, 2006; Greenfield
et al., 2009). Thus, understanding the
molecular mechanisms responsible for
regulating MC4 signaling may lead tobetter therapies targeting body weight
and glucose homeostasis. Now, com-
panion articles (Asai et al., 2013; Sebag
et al., 2013) in the journal Science add
a new layer of complexity to the regula-
tion of MC4 receptors. They report that
melanocortin receptor accessory protein
2 (Mrap2) coordinates signaling by MC4
receptors and demonstrate that Mrap2
is required for growth and development,
as well as metabolism, across species
including humans (Asai et al., 2013;
Sebag et al., 2013).
MC4 receptors are G protein-coupled
receptors (GPCRs) that stimulate
classical signaling cascades, which ulti-
mately regulate metabolism at least in
part via expression in sites involved in
autonomic and endocrine function,
including the paraventricular nucleus of
the hypothalamus (PVH) (Balthasar
et al., 2005; Cone, 2006). However,
recent work suggests that melanocortin
signaling is more complicated than pre-
viously anticipated. In particular, mela-nocortin receptor accessory proteins
(Mrap1 and Mrap2) regulate transport
of melanocortin receptors to the cell
membrane and also abrogate or facili-
tate ligand-induced activation of intracel-
lular signaling (Ramachandrappa et al.,
2013). Asai et al. now demonstrate that
Mrap2 is highly expressed in the PVH,
including cells expressing the MC4 re-
ceptor (Asai et al., 2013; Cone, 2006).
In agreement with Mrap2 playing a role
in MC4 receptor signaling (Figure 1),
they also find that rodents deficient for
Mrap2 are obese even in the absence
of excess food. Moreover, selective
loss of Mrap2 in neurons expressing
the transcription factor single-minded 1
(Sim1) recapitulates the obese pheno-
type observed in global Mrap2 defi-
ciency, consistent with the notion that
Sim1 neurons expressing MC4 receptors
are key regulators of energy balance
(Balthasar et al., 2005; Holder et al.,
2000). Notably, Asai and colleagues
found four rare heterozygous variantseptember 3, 2013 ª2013 Elsevier Inc. 309
